Zacks Research Comments on Eli Lilly and Company’s Q1 2025 Earnings (NYSE:LLY)

Eli Lilly and Company (NYSE:LLY) – Research analysts at Zacks Research reduced their Q1 2025 earnings per share estimates for Eli Lilly and Company in a report released on Wednesday, April 17th. Zacks Research analyst K. Shah now expects that the company will post earnings of $4.77 per share for the quarter, down from their previous forecast of $4.80. The consensus estimate for Eli Lilly and Company’s current full-year earnings is $12.52 per share. Zacks Research also issued estimates for Eli Lilly and Company’s Q2 2025 earnings at $4.07 EPS, Q3 2025 earnings at $4.46 EPS, Q4 2025 earnings at $4.50 EPS and FY2025 earnings at $17.80 EPS.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. During the same period in the prior year, the firm earned $2.09 earnings per share. The company’s quarterly revenue was up 28.1% compared to the same quarter last year.

A number of other research firms also recently issued reports on LLY. JPMorgan Chase & Co. upped their target price on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a research report on Friday, March 15th. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. DZ Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target for the company. in a research note on Wednesday, February 21st. Bank of America increased their target price on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $815.00 price target on shares of Eli Lilly and Company in a report on Monday. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $728.05.

Eli Lilly and Company Trading Down 0.6 %

LLY opened at $745.95 on Thursday. Eli Lilly and Company has a 1-year low of $367.35 and a 1-year high of $800.78. The stock has a market capitalization of $708.77 billion, a PE ratio of 128.61, a PEG ratio of 1.63 and a beta of 0.34. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. The firm has a 50-day moving average price of $764.24 and a two-hundred day moving average price of $658.28.

Insiders Place Their Bets

In related news, major shareholder Lilly Endowment Inc sold 54,032 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $645.07, for a total transaction of $34,854,422.24. Following the completion of the sale, the insider now directly owns 99,488,598 shares of the company’s stock, valued at approximately $64,177,109,911.86. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 0.13% of the company’s stock.

Institutional Trading of Eli Lilly and Company

Institutional investors have recently added to or reduced their stakes in the company. Lipe & Dalton acquired a new position in Eli Lilly and Company in the 4th quarter worth about $26,000. Thompson Investment Management Inc. bought a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at about $27,000. Retirement Group LLC grew its position in shares of Eli Lilly and Company by 159.1% in the 2nd quarter. Retirement Group LLC now owns 57 shares of the company’s stock valued at $27,000 after buying an additional 35 shares during the last quarter. Tidemark LLC bought a new stake in shares of Eli Lilly and Company in the 4th quarter valued at about $29,000. Finally, Core Wealth Advisors Inc. boosted its position in shares of Eli Lilly and Company by 188.2% during the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after purchasing an additional 32 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.